Literature DB >> 7514689

Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.

K L Blackwell1, D G Bostwick, R P Myers, H Zincke, J E Oesterling.   

Abstract

The serum prostate specific antigen (PSA) level was determined in 311 men with documented prostate cancer (stages T1cN0, T2N0 and T3N0) before bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. The prostates were whole mounted, serially sectioned, and examined for cancer volume, capsular perforation, seminal vesicle invasion, lymph node involvement, Gleason grade, nuclear grade and nuclear deoxyribonucleic acid content. Median serum PSA level was significantly different between cancers that were organ confined, those that had capsular perforation or seminal vesicle invasion and those with positive lymph nodes (p < 0.001). Median serum PSA level was also significantly different between tumors with Gleason scores of less than 6 and those with higher Gleason scores (p < 0.001), and between tumors with greater than 30% of poorly differentiated cancer (Gleason primary grades 4 and 5) and those with 30% or less poorly differentiated cancer (p < 0.001). Bivariate analysis revealed that the strongest correlations of serum PSA level were with cancer volume (r = 0.56), per cent of poorly differentiated cancer (r = 0.42), positive surgical margins (r = 0.39) and pathological stage (r = 0.38), for all p < 0.001. Multivariate analysis showed that cancer volume was the major contributor to serum PSA level. The derivative, PSA-cancer density (serum PSA times cancer volume divided by prostate volume), accounted for the effects of prostate volume and cancer volume on serum PSA. PSA-cancer density showed a significant correlation with pathological stage (r = 0.56), Gleason score (r = 0.53) and per cent of poorly differentiated cancer (r = 0.49, for all p < 0.001), and these correlations were significantly stronger than serum PSA level alone or PSA density (serum PSA divided by prostate volume; volume determined from tissue specimens) for all variables. These results indicate that preoperative serum PSA level has significant predictive value in determining tumor burden and pathological stage, and this predictive value is increased by accounting for cancer and gland volume with PSA-cancer density.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514689     DOI: 10.1016/s0022-5347(17)35303-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes.

Authors:  Julie C Bulman; Robert Toth; Amish D Patel; B Nicolas Bloch; Colm J McMahon; Long Ngo; Anant Madabhushi; Neil M Rofsky
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

2.  Tissue shrinkage after fixation with formalin injection of prostatectomy specimens.

Authors:  Sara Jonmarker; Alexander Valdman; Anna Lindberg; Magnus Hellström; Lars Egevad
Journal:  Virchows Arch       Date:  2006-08-15       Impact factor: 4.064

Review 3.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 4.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 5.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

6.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

7.  Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer?

Authors:  W F Thon; F Gadban; M C Truss; M Kuczyk; U Hartmann; U Jonas
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

8.  The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.

Authors:  Erim Erdem; Necmettin Atsü; Cem Akbal; Cenk Y Bilen; Ali Ergen; Haluk Ozen
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 9.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.

Authors:  John Kurhanewicz; Mark G Swanson; Sarah J Nelson; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

10.  Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.

Authors:  Raphael Barroso Kato; Victor Srougi; Fernanda Aburesi Salvadori; Pedro Paulo Marino Rodrigues Ayres; Katia Moreira Leite; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.